WHO ICTRP trial
Phase II/III Trial of DFP-17729 in Patients with Unresectable, Recurrent, or…
JPRN-jRCT2031250195 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031250195 |
|---|---|
| Public title | Phase II/III Trial of DFP-17729 in Patients with Unresectable, Recurrent, or Advanced Pancreatic Cancer |
| Scientific title | Phase II/III Trial of DFP-17729 in Patients with Unresectable, Recurrent, or Advanced Pancreatic Cancer |
| Primary sponsor | Iizuka Kenzo |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2-3 |
| Conditions | Pancreatic cancer |
| Interventions | - Investigational product (DFP-17729) or control (placebo): Oral administration, 24 tablets per day, divided into four doses, administered daily. - Concomitant medication (S-1): To be administered at a dose and schedule deemed appropriate… |
| Registration date | Jan 7, 2025 |
| Target size | 258 |
| Registry page | jrct.mhlw.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: